title: Bortezomib, Melphalan, and Prednisone (VMP) Regimen for Multiple Myeloma.
abstract: The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.
authors: Dr. Bryant is a Pharmacy Practice Resident (PGY1) at Peninsula Regional Medical Center , Salisbury, Maryland . At the time this manuscript was written, Dr. Bryant was a student at the Philadelphia College of Pharmacy, University of the Sciences.
authors: Samantha
authors: S
authors: Bryant
authors: Dr. Bryant is a Pharmacy Practice Resident (PGY1) at Peninsula Regional Medical Center , Salisbury, Maryland . At the time this manuscript was written, Dr. Bryant was a student at the Philadelphia College of Pharmacy, University of the Sciences.
authors: Dominic A
authors: DA
authors: Solimando
authors: Dr. Bryant is a Pharmacy Practice Resident (PGY1) at Peninsula Regional Medical Center , Salisbury, Maryland . At the time this manuscript was written, Dr. Bryant was a student at the Philadelphia College of Pharmacy, University of the Sciences.
authors: J Aubrey
authors: JA
authors: Waddell